Altimmune, Inc.
ALT Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$2.05
KIRA · Stoqly’s AI analyst, in plain words
- Altimmune, Inc. had $0.0M of revenue in fiscal 2025, up 105.0% on the year before. Over five years, revenue changed −65.3% a year on average.
- Its operating margin was −230,461.0%, up 285,399.0 pts: of every 100 in sales, about −230,461 is left after running the business.
- Altimmune, Inc. lost $88.1M in fiscal 2025.
- Free cash flow was −$67.5M in fiscal 2025, −164,746.3% of revenue.
- Altimmune, Inc. has $239M more cash than debt.
Market cap
$380M
P/E
—
Revenue
$0.0M
Net income
−$88.1M
Free cash flow
−$67.5M
Operating margin
−230,461.0%
Altimmune, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+105.0%
Yes. Sales grew 105.0% last year.
Does it make a profit?
−214,861.0%
No. It lost money last year.
Does profit turn into cash?
−164,746.3%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 7
Mixed. It passes 4 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Altimmune, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 6, 2026
- Legal name
- Altimmune, Inc.
- CIK
- 0001326190
Altimmune, Inc. · ALT
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $4.4M | −$0.1M | $0.4M | $0.0M | $0.0M |
| Revenue growth | −46.1% | −101.5% | — | −95.3% | 105.0% |
| Operating margin | −2,197.6% | 129,029.4% | −22,518.5% | −515,860.0% | −230,461.0% |
| Net income | −$97.1M | −$84.7M | −$88.4M | −$95.1M | −$88.1M |
| Net margin | −2,201.6% | 124,577.9% | −20,762.2% | −475,295.0% | −214,861.0% |
| Diluted EPS | −$2.35 | −$1.81 | −$1.66 | −$1.34 | −$1.00 |
| Cash | |||||
| Cash from operations | −$78.2M | −$62.6M | −$75.8M | −$79.8M | −$67.5M |
| Capital expenditure | $12.1M | $0.1M | $0.0M | — | $0.0M |
| Free cash flow | −$90.4M | −$62.7M | −$75.9M | — | −$67.5M |
| FCF margin | −2,048.9% | 92,223.5% | −17,806.8% | — | −164,746.3% |
| Share count change | 61.0% | 13.7% | 13.5% | 33.3% | 24.1% |
| Debt and strength | |||||
| Cash and short-term investments | $190M | $185M | $198M | $132M | $273M |
| Debt incl. finance leases | $1.5M | $4.6M | — | — | $34.3M |
| Shareholders' equity | $199M | $185M | $194M | $124M | $225M |
| Current ratio | 11.2x | 11.3x | 17.3x | 13.1x | 18.5x |
| Interest coverage | −19,382.8x | −10,967.5x | −2,740.8x | −11,463.6x | −57.8x |
| Returns and quality | |||||
| Return on capital | −744.2% | −1,388.0% | — | — | — |
| Return on equity | −45.7% | −44.1% | −46.6% | −59.9% | −50.6% |
| Return on tangible equity | −52.0% | −49.0% | −45.6% | −77.0% | −39.2% |
| Piotroski F-score | 2 | 3 | 3 | 1 | 4 |
| Altman Z'' | 8.8 | 5.8 | 8.2 | −3.9 | 0.6 |
Insiders bought, 12 months
$0.4M
6 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Altimmune, Inc. · ALT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.05 a share, the company is worth $380M.
Source: SEC EDGAR XBRL filings (CIK 0001326190). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.